MARKET

TELA

TELA

TELA BIO, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.43
+0.16
+1.05%
Opening 15:43 09/25 EDT
OPEN
14.84
PREV CLOSE
15.27
HIGH
15.58
LOW
14.84
VOLUME
14.45K
TURNOVER
--
52 WEEK HIGH
23.55
52 WEEK LOW
5.25
MARKET CAP
222.41M
P/E (TTM)
-6.4054
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Additional data shows durable outcome for TELA Bio' tissue matrix for hernia repair
TELA Bio (TELA) has announced additional data from its BRAVO study with OviTex tissue matrix. Data were presented at the Americas Hernia Society Annual Meeting.30-day data from 85 subjects demonstrated that ventral hernia
Seekingalpha · 7h ago
TELA Bio Highlights Presentation Of Additional Data From BRAVO Study Of OviTex For Ventral Hernia Repair
MALVERN, Pa., Sept. 25, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcementMALVERN, Pa., Sept. 25, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc.
Benzinga · 8h ago
TELA Bio Presents Additional Data from BRAVO Study of OviTex® for Ventral Hernia Repair
MALVERN, Pa., Sept. 25, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that
GlobeNewswire · 8h ago
TELA Bio to Participate at Upcoming Conferences
MALVERN, Pa., Sept. 02, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced today that
GlobeNewswire · 09/02 11:00
TELA Bio Q2 EPS $(0.53) Beats $(0.59) Estimate, Sales $3.51M Beat $1.93M Estimate
TELA Bio (NASDAQ:TELA) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.59) by 10.17 percent. This is a 98.04 percent increase over losses of $(27.06) per share from the
Benzinga · 08/12 20:23
TELA Bio EPS beats by $0.01, beats on revenue
TELA Bio (TELA): Q2 GAAP EPS of -$0.53 beats by $0.01.Revenue of $3.51M (+6.4% Y/Y) beats by $1.21M.Press Release
Seekingalpha · 08/12 20:10
TELA Bio EPS beats by $0.01, beats on revenue
TELA Bio (TELA): Q2 GAAP EPS of -$0.53 beats by $0.01.Revenue of $3.51M (+6.4% Y/Y) beats by $1.21M.Press Release
Seekingalpha · 08/12 20:10
The Daily Biotech Pulse: India Globalization Gets Nod For Alzheimer's Trial, Moderna's Vaccine Deal With US, Cellular Biomedicine To Go Private
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11)
Benzinga · 08/12 11:29
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TELA. Analyze the recent business situations of TELA BIO, INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TELA stock price target is 19.75 with a high estimate of 24.00 and a low estimate of 17.00.
EPS
Institutional Holdings
Institutions: 56
Institutional Holdings: 9.90M
% Owned: 68.69%
Shares Outstanding: 14.41M
TypeInstitutionsShares
Increased
18
2.53M
New
34
880.33K
Decreased
2
3.38K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+1.75%
Healthcare Equipment & Supplies
+1.73%
Key Executives
Chairman/Independent Director
Kurt Azarbarzin
Chairman/Independent Director
Douglas Evans
President/Chief Executive Officer/Co-Founder/Director
Antony Koblish
Co-Founder
Maarten Persenaire
Chief Technology Officer
Skott Greenhalgh
Chief Financial Officer
Nora Brennan
Chief Technology Officer
Ellis Greenhalgh
Other
Peter Murphy
Independent Director
kurt Azarbarzin
Independent Director
Vince Burgess
Independent Director
Lisa Colleran
Independent Director
Federica OBrien
Independent Director
Adele Oliva
Independent Director
Matt Zuga
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About TELA
TELA Bio Inc. is a medical technology company. The Company is focused on designing, developing and marketing tissue reinforcement materials for soft tissue reconstruction. It offers a portfolio of products and solutions for care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. Its portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), can be used for ventral hernia repair and abdominal wall reconstruction, inguinal hernia repair and hiatal hernia repair. Its OviTex PRS Reinforced Tissue Matrix (OviTex PRS) addresses needs in plastic and reconstructive surgery. OviTex PRS product is designed for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of TELA Bio Inc stock information, including NASDAQ:TELA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TELA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TELA stock methods without spending real money on the virtual paper trading platform.